Animal models of sepsis and shock: A review and lessons learned

Shock

Volumn 9, Issue 1, 1998, Pages 1-11

  Deitch, Edwin A ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BACTERIAL INFECTION; DISEASE MODEL; EPIDEMIOLOGY; HEMORRHAGIC SHOCK; HUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS; SHOCK;

ANIMALS; BACTERIAL INFECTIONS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE MODELS, ANIMAL; HUMANS; RANDOMIZED CONTROLLED TRIALS; SEPSIS; SHOCK; SHOCK, HEMORRHAGIC;

EID: 0031606321     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199801000-00001     Document Type: Review

References (52)

1. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA: A controlled trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317:653-658, 1987.
2. Veterans Administration Systemic Sepsis Cooperative Group: Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 317:659-665, 1987.
3. Ziegler EJ, Fisher CJ, Sprung CL, et al: Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: A randomized, double-blind, placebo-controlled trial. N Engl J Med 324:429-436, 1991.
4. Greenman RL, Schein RMH, Martin MA, et al: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. J Am Med Assoc 266:1097-1102, 1991.
5. Dhainaut JFA, Tenaillon A, LeTulzo Y, et al: Platelet-activating factor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 22:1720-1728, 1994.
6. Fisher CJ, Dhainaut JFA, Opal SM, et al: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. J Am Med Assoc 271:1836-1843, 1994.
7. Bone RC, Balk RA, Fein AM, et al: A second large controlled clinical study of E5 a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 23:994-1006, 1995.
8. Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome: A randomized, controlled, double-blind, multicenter clinical trial. J Am Med Assoc 273:934-941, 1995.
9. Cohen J, Carlet J: INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med 24:1431-1440, 1996.
10. Fisher CJ, Agosti JM, Opal SM, et al: Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 334:1697-1702, 1996.
11. Abraham E, Glauser MP, Butler T, et al: P55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: A randomized controlled multicenter trial. J Am Med Assoc 277:1531-1538, 1997.
12. Bernard GR, Wheeler AP, Russell JA, et al: The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 336: 912-918, 1997.
13. Wichterman KA, Baue AE, Chaudry IH: Sepsis and septic shock: A review of laboratory models and a proposal. J Surg Res 29:189-201, 1980.
14. Fink MP, Heard SO: Laboratory models of sepsis and septic shock. J Surg Res 49:186-196, 1990.
15. Cross AS, Opal SM, Sadoff JC, Gemski P: Choice of bacteria in animal models of sepsis. Infect Immun 61:2741-2747, 1993.
16. Piper RD, Cook DJ, Bone RC, Sibbald WJ: Introducing critical appraisal to studies of animal models investigating novel therapies in sepsis. Crit Care Med 24:2059-2070, 1996.
17. Dellinger P: Post hoc analyses in sepsis trials: A formula for disappointment? Crit Care Med 24:727-729, 1996.
18. Ahrenholz DH, Simmons RL: Fibrin in peritonitis. I. Beneficial and adverse effects of fibrin in experimental E. coli peritonitis. Surg 88:41-47, 1980.
19. Natanson C, Fink MP, Ballantyne HK, MacVittie TJ, Conklin JJ, Parillo JE: Gram-negative bacteremia produces both severe systolic and diastolic dysfunction in a canine model that simulates human septic shock. J Clin Invest 78:259-270, 1986.
20. Fink MP, MacVittie TJ, Casey LC: Inhibition of prostaglandin synthesis restores normal hemodynamics in canine hyperdynamic sepsis. Ann Surg 200:619-626, 1984.
21. 100 Escherichia coli. Ann Surg 194:51-56, 1981.
22. Tracey KJ, Fong Y, Hesse G, et al: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330:662-666: 1987.
23. Shaw JHF, Wolfe RR: A conscious septic dog model with hemodynamic and metabolic responses similar to responses of humans. Surg 95:553-561, 1984.
24. Porat R, Mosseri R, Kaplan E, Johns MA, Shibolet S: Distribution of polysaccharide side chains of lipopolysaccharide determine resistance of Escherichia coli to the bactericidal activity of serum. J Infect Dis 165: 953-956, 1992.
25. Zanetti G, Heumann D, Gerain J, et al: Cytokine production after intravenous or peritoneal Gram-negative bacterial challenge in mice: Comparative protective efficacy of antibodies to TNF and to LPS. J Immunol 148:1890-1897, 1992.
26. Evans GF, Snyder YM, Butler LD, Zuckerman SH: Differential expression of interleukin-1 and tumor necrosis factor in murine septic shock models. Circ Shock 29:279-290, 1989.
27. Bagby GJ, Plessala KJ, Wilson LA, Thompson JJ, Nelson S: Divergent efficacy of antibody to tumor necrosis factor in intravascular and peritonitis models of sepsis. J Infect Dis 163:83-88, 1991.
28. Cross AS, Sadoff JC, Bernton NK, Gemski P: Pretreatment with recombinant murine tumor necrosis factor and murine interleukin-1 protects mice from lethal infection. J Exp Med 169:2021-2027, 1989.
29. Reinhart K, Wiegand-Lohnert C, Grimminger F, et al: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 24:733-742, 1996.
30. Teng NNH, Kaplan HS, Hebert JM, et al: Protection against Gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Natl Acad Sci USA 82:1790-1794, 1985.
31. Quezado Z, Natanson C, Ailing DW, et al: A controlled trial of HA-1A in a canine model of Gram-negative septic shock. J Am Med Assoc 269: 2221-2227, 1993.
32. Bellemy RF, Maningas PA, Wenger BA: Current shock models and clinical correlations. Ann Emerg Med 15:1392-1395, 1986.
33. Cannon WB, Fraser J, Cowell EM: The preventive treatment of wound shock. J Am Med Assoc 70:618-621, 1918.
34. Velasco IT, Pontieri V, Rochae Silva M, Lopes OU: Hyperosmotic NaCl, severe hemorrhagic shock. Am J Physiol 239:H664-H673: 1980.
35. Smith GJ, Kramer GC, Perron PR, Nakayama S, Gunther RA, Holcroft JW: A comparison of several hypertonic solutions for resuscitation of bled sheep. J Surg Res 39:517-528, 1985.
36. Vassar NJ, Perry CA, Gannaway WL, Holcroft JW: 7.5% sodium chloride/ dextran for resuscitation of trauma patients undergoing helicopter transport. Arch Surg 126:1065-1072, 1991.
37. Gross D, Landau EH, Assalia A, Krauz MM: Is hypertonic saline resuscitation safe in "uncontrolled" hemorrhagic shock. J Trauma 28:751-756, 1988.
38. Committee on Trauma. American College of Surgeons Advanced Trauma Life Support Program Instructor's Manual. Chicago: American College of Surgeons, 1993, pp 75-94.
39. Bickell WH, Wall MJ, Pepe PE, et al: Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med 331:1105-1109, 1994.
40. Shaftan GW, Chiu CJ, Dennis C, Harris B: Fundamentals of physiologic control of arterial hemorrhage. Surg 58:851-856, 1965.
41. Bickell WH, Bruttig SP, Millnamow GA, O'Benar J, Wade CE: The detrimental effects of intravenous crystalloid after aortotomy in swine. Surgery 110:529-536, 1991.
42. Bickell WH, Bruttig SP, Millnamow GA, O'Benar J, Wade CE: Use of hypertonic saline/dextran versus Ringer's lactate solution as a resuscitation fluid after uncontrolled aortic hemorrhage in anesthetized swine. Ann Emerg Med 21:1077-1085, 1992.
43. Capone A, Safar P, Stezoshi W, Tisherman S, Pietzman AB: Improved outcome with fluid resuscitation in treatment of uncontrolled hemorrhagic shock. J Am Coll Surg 180:49-56, 1995.
44. Zellweger R, Ayala A, Stein S, DeMaso CM, Chaudry IH: Females in proestrus state tolerate sepsis better than males. Surg Forum 46:65-67, 1995.
45. Wichmann M, Zellweger R, Ayala A, DeMaso CM, Chaudry IH: Gender differences: improved immune function in females as opposed to decreased immune function in males following hemorrhagic shock. Surg Forum 46:758-759, 1995.
46. Wichmann M, Zellweger R, DeMaso CM, Ayala A, Chaudry IH: Mechanism of immune suppression in males following trauma-hemorrhage: Critical role of testosterone. Arch Surg 131:1186-1192, 1996.
47. Rapaport FT, Bachvaroff RJ, Grullon J, Kunz H, Gill TJ III: Genetics of natural resistance to thermal injury. Ann Surg 195:294-305, 1982.
48. Deitch EA, Ma L, Ma JW, Berg RD: Lethal burn-induced bacterial translocation: Role of genetic resistance. J Trauma 29:1480-1487, 1989.
49. Stuber F, Petersen M, Bokelmann F, Schade U: A genetic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-α concentrations and outcomes of patients with severe sepsis. Crit Care Med 24:381-384, 1996.
50. Wiggers CJ: The present state of the shock problem. Physiol Rev 22:74-123, 1942.
51. Rana MW, Singh G, Wang P, Ayala A, Zhou M, Chaudry IH: Protective effects of preheparinization on the microvasculature during and after hemorrhagic shock. J Trauma 32:420-426, 1992.
52. Rokke O, Revhaug A, Osterud B, Gierchsky KE: Increased plasma levels of endotoxin and corresponding changes in circulatory performance in a porcine sepsis model: The effect of antibiotic administration. Prog Clin Biol Res 272:247-262, 1988.